TABLE 1.
EORTC QLQ-C30 and EORTC QLQ-HCC18 PRO Scores at Baseline
| Scale/Item | STRIDE (n = 393), Mean (SD) | Durvalumab (n = 389), Mean (SD) | Sorafenib (n = 389), Mean (SD) |
|---|---|---|---|
| EORTC QLQ-C30 | |||
| GHS/QoL | 70.5 (18.89) | 69.9 (18.87) | 67.4 (19.94) |
| Functional—physical functioning | 84.6 (16.54) | 84.4 (16.32) | 81.0 (20.52) |
| Functional—role | 84.7 (21.69) | 84.9 (21.92) | 80.5 (26.91) |
| Multiple symptoms—fatigue | 26.2 (20.73) | 24.9 (20.49) | 31.3 (25.65) |
| Single item—appetite loss | 12.2 (21.02) | 14.3 (25.06) | 17.8 (25.61) |
| Single item—nausea | 7.5 (17.84) | 7.4 (18.21) | 9.8 (21.24) |
| Single item—diarrhea | 6.0 (15.91) | 5.4 (13.40) | 7.6 (16.07) |
| EORTC QLQ-HCC18 | |||
| Single item—shoulder pain | 14.1 (22.37) | 15.0 (23.32) | 18.0 (26.70) |
| Single item—abdominal pain | 15.5 (21.45) | 13.0 (19.62) | 17.7 (24.70) |
| Single item—abdominal swelling | 11.9 (21.49) | 12.3 (21.39) | 12.0 (21.07) |
| Multiple symptoms—jaundice | 8.5 (14.18) | 8.6 (13.38) | 10.9 (16.14) |
Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; HCC, hepatocellular carcinoma; PRO, patient-reported outcome; QLQ-C30, 30-item Quality of Life Questionnaire; QLQ-HCC18, 18-item HCC Health-Related Quality of Life Questionnaire; QoL, quality of life; SD, standard deviation; STRIDE, Single Tremelimumab Regular Interval Durvalumab.